Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Photocure clinical trials
The registry lists 23 studies whose lead sponsor is Photocure. 2 are recruiting or about to start. Per ClinicalTrials.gov, last updated Sep 4, 2026.
Keep track of what changes. Save the Photocure studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesRegistry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Photocure.
- Photocure23 studiesSame company
Something wrong?
Focus areas
Conditions Photocure leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.
Studies
Recruiting first, then most recently updated. Showing 23 of 23.
- Exploration of Novel AI-enabled Blue Light Enhanced CystoscopyRecruitingNCT07144319
- Blue Light Cystoscopy With Cysview® RegistryRecruitingNCT02660645
- Comparative Study of Hexvix Blue Light Cystoscopy and White Light Cystoscopy in the Detection of Bladder CancerCompletedNCT05600322Phase 3
- Longer-term Recurrence Rates in Patients With Bladder Cancer After Hexvix (Cysview)Fluorescence Cystoscopy/TURBCompletedNCT01166230
- A Study of Blue Light Flexible Cystoscopy With Cysview in the Detection of Bladder Cancer in the Surveillance SettingCompletedNCT02560584Phase 3
- Dose-finding Study of Hexaminolevulinate (HAL) Photodynamic Therapy (PDT) to Treat Cervical NeoplasiaCompletedNCT01256424Phase 2
- Photoactive Porphyrins (PAP) Levels After Topical Visonac Application in Acne PatientsCompletedNCT01160848Phase 2
- A Double Blinded, Prospective, Randomized, Vehicle Controlled Multi-center Study of Photodynamic Therapy With Visonac® Cream in Patients With Acne VulgarisCompletedNCT01347879Phase 2
- Efficacy and Safety Study With Visonac Photodynamic Therapy (PDT)CompletedNCT00933543Phase 2
- An Open Dose-finding Study of Oral Applied Hexaminolevulinate (HAL) Imaging in Patients With Suspicion or High Risk of Neoplasia in the ColonTerminatedNCT01344902Phase 1/2
- Cystoscopy and Hexyl 5-Aminolevulinate in Detecting Carcinoma In Situ in Patients With Bladder CancerCompletedNCT00052637Phase 3
- Study to Improve Detection and Early Recurrence Rate in Bladder Cancer Patients Using Hexvix Fluorescence CystoscopyCompletedNCT00233402Phase 3
- A Randomized, Comparative Study of Hexvix Fluorescence Cystoscopy and Standard Cystoscopy in Patients With Non-invasive Bladder CancerCompletedNCT00412971Phase 3
- Photodynamic Therapy (PDT) With Methyl Aminolevulinate (MAL) Cream in Moderate to Severe AcneCompletedNCT00594425Phase 2
- Photodynamic Therapy (PDT) With Methyl Aminolevulinate (MAL) Cream in Patients With Skin Type V or IV With Acne VulgarisCompletedNCT00673933Phase 2
- Hexaminolevulinate (HAL) Photodynamic Therapy (PDT) of Cervical Intraepithelial Neoplasia (CIN) Grade 1TerminatedNCT00708942Phase 2
- Detection of Bladder Tumors After 30 Min Instillation of HexvixTerminatedNCT01551407Phase 2
- Hexvix Photodynamic Therapy in Patients With Bladder CancerCompletedNCT01303991Phase 1
- A Dose-finding Study of MAL and HAL Photodynamic Therapy of Cervical Premalignant Lesions.CompletedNCT00369018Phase 1/2
- Early Detection of Polyps and Colon Cancer by Fluorescence Imaging - a Dose-finding StudyCompletedNCT00285701Phase 1/2
- An Open-label, Single-dose, Three Period Study to Determine the Pharmacokinetic Parameters of Hexaminolevulinate (HAL) Hydrochloride After Vaginal, Enema and Intravenous Administration of Healthy Female VolunteersCompletedNCT01050309Phase 1
- Safety and Efficacy Study of Topical Methyaminlevulinate (MAL) in Subjects With Facial AcneCompletedNCT00833183Phase 2
- Phase I Study of HAL Formulations Applied to the Cervix in Healthy VolunteersTerminatedNCT00496171